Federal judge orders block on parts of HHS reorganization plan after states sue
A Rhode Island judge on Tuesday issued a preliminary injunction against parts of the Trump administration’s plan to restructure the federal health agencies. “The States have shown a likelihood of...
View ArticleShionogi, BioVersys team up on ansamycin antibiotics in deal worth up to $614M
BioVersys is entering a pact with Shionogi to advance the Swiss biotech’s antibiotic program targeting non-tuberculous mycobacteria, with over half a billion dollars in biobucks on the line. Shionogi...
View ArticleSoriot mulls moving AstraZeneca stock listing to the US — report
AstraZeneca CEO Pascal Soriot is reportedly considering moving the company’s stock listing from the UK to the US. He also privately mooted the idea of changing the pharma company’s domicile, according...
View ArticleOrganon stops work on drug once viewed as ‘game-changing’; NextPoint culls an...
Plus, news about ArriVent BioPharma, Everest Medicines, Ribocure, Paradigm Biopharmaceuticals, Verrica and Torii: Organon discontinues experimental therapy for endometriosis-related pain: The Merck...
View ArticleUS investors divided on China's biotech rise
China’s ascent in drug development has kicked off debate among American investors over how to respond. Chinese companies are now competitive in some of the hottest areas of drug research, including...
View ArticleAbbVie cans oral ulcerative colitis drug from Landos buyout
AbbVie terminated work on the main drug from last year's $137 million buyout of Landos Biopharma. It's an abrupt end for ABBV-113, formerly known as NX-13, in ulcerative ...
View ArticleVyne stops enrolling early-stage psoriasis study following clinical hold...
Vyne Therapeutics made several announcements Wednesday regarding its early-stage inflammatory disease asset, culminating in the decision to stop enrolling patients in a Phase 1b psoriasis study. It’s...
View ArticleAfter delay, Regeneron wins US approval of bispecific in multiple myeloma
At long last, Regeneron is bringing a bispecific antibody drug for multiple myeloma to the US market. The company said Wednesday that linvoseltamab was granted accelerated approval for adults with...
View ArticleCDC expands RSV vaccine recommendations, siding with previous panel of agency...
The CDC will recommend RSV vaccines for all at-risk adults in their 50s, expanding its current guidance on the shots and siding with the agency's former panel of vaccine experts. HHS Secretary Robert...
View ArticleAbbVie loses bid to block Tennessee's 340B contract pharmacy law
AbbVie failed to persuade a federal judge to block a recent Tennessee law that aims to regulate drugmaker discount policies under the federal 340B program. The decision is another blow to...
View ArticleBristol Myers' China partner touts Phase 3 success for EGFRxHER3 bispecific ADC
Bristol Myers Squibb’s foray into cancer antibody-drug conjugates and bispecifics appears to be bearing fruit. Chinese startup Biokin, which partnered with Bristol Myers through its subsidiary...
View ArticleHow FDA staff defied Prasad’s vaccine framework in Moderna review
Reviewers at the FDA recommended that Moderna’s next-gen Covid-19 vaccine be approved for all people 12 and older who previously received a shot, defying a new framework unveiled by agency leadership...
View ArticleDizal’s lung cancer pill approval sets up competition with J&J
Dizal said that its EGFR inhibitor sunvozertinib has been approved by the FDA for certain types of lung cancer. The pill, now branded as Zegfrovy, gained accelerated approval in the US for locally...
View ArticleNow private, bluebird bio continues leadership revamp; Roche R&D exec...
Bluebird bio rolled out three new executive hires on Tuesday: Brian Riley as president and chief technical officer, Joanne Lager as chief medical officer and Adrian Chaisson as ...
View Article4DMT lays off staff, reshuffles team as it doubles down on Phase 3 plans
As 4D Molecular Therapeutics prepares to shift into a late-stage clinical biotech, it is letting go of a quarter of its staffers and pruning its leadership team. The California drugmaker will lay off...
View ArticleSage talked to 43 'counterparties' before inking Supernus deal
Sage Therapeutics talked with 43 "counterparties" over the course of last year and early 2025 as the 15-year-old company sought a lifeline for its grand ambitions, according to new regulatory
View ArticleBioSpring embarks on €100M+ nucleic acid factory in Germany
German oligonucleotide CDMO BioSpring is expanding its footprint in its home country, budgeting over €100 million ($106 million) to build a new nucleic acid factory in Offenbach. The...
View ArticleStructure in partnering talks for oral GLP-1 as mid-stage readout nears
It is a truth universally acknowledged that a biotech in possession of a mid-stage GLP-1 must be in want of a partner. Structure Therapeutics is no exception. With Phase 2 trials of its obesity pill ...
View ArticleNumber of megarounds drops 38% in first half as biotechs struggle against...
Even biotech's "haves" are struggling. The sector's fraught funding environment has been in a slump going on three years, and it's created a world of "haves and have-nots" for private drug development...
View ArticleTorrent Pharma’s $1.38B JB Chemicals takeover; Future Pak to buy...
Welcome to Endpoints News’ manufacturing briefs, where we bring you essential news on new builds, collaborations, recalls and more. Torrent Pharmaceuticals will purchase roughly a 46% stake in JB...
View ArticleCloudbreak’s shares stumble in Hong Kong debut; Sinovac squares off against...
Plus, news about BrainEver, Clinigen, MaaT Pharma, Dyadic and Nektar Therapeutics: Cloudbreak Pharma shares fall in Hong Kong debut: The ophthalmology biotech, which has offices in California and...
View ArticleNovartis' Cosentyx fails Phase 3 study for autoimmune disease
Novartis faced a setback in its ambition to expand its blockbuster drug Cosentyx and compete in an autoimmune condition with products from Roche and AbbVie. The company said Thursday that the drug...
View ArticleJudge rules against Trump administration's removal of HHS web content
The Trump administration's actions to remove a broad swath of HHS webpages in late January were arbitrary and not the “product of reasoned decisionmaking,” a federal district court ruled Thursday. The
View Article